PF-489791

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-489791
Drug Alias NamePF-00489791PF-0489791PF-489791
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitors
TargetsPhosphodiesterase 5A
Therapy Area/IndicationsRaynaud DiseasePeripheral Vascular DiseasesHypertension +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsRaynaud DiseasePeripheral Vascular DiseasesHypertension +[6] 

Other Information

ATC CodeN/A
Related LinksN/A